PriceTargets.com logo

Cumberland Pharmaceuticals - CPIX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.73 As of 01/27/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for CPIX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cumberland Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CPIX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CPIX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cumberland Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.73.

This chart shows the closing price for CPIX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Cumberland Pharmaceuticals. This rating has held steady since March 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2021B. RileyReiterated RatingBuyLow
3/19/2020B. RileyReiterated RatingBuyLow
12/3/2019B. RileyBoost TargetBuy$9.00 ➝ $9.75Medium
8/17/2018B. RileyLower TargetBuy ➝ Buy$9.25 ➝ $8.75Medium
4/17/2018B. RileyInitiated CoverageBuy$9.25High
(Data available from 1/29/2018 forward)

News Sentiment Rating

-0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 26 positive mentions
  • 12 negative mentions
  • 14 very negative mentions
Mentions as of
7/3/2022
  • 4 very positive mentions
  • 15 positive mentions
  • 6 negative mentions
  • 13 very negative mentions
Mentions as of
8/2/2022
  • 2 very positive mentions
  • 27 positive mentions
  • 10 negative mentions
  • 7 very negative mentions
Mentions as of
9/1/2022
  • 4 very positive mentions
  • 40 positive mentions
  • 9 negative mentions
  • 16 very negative mentions
Mentions as of
10/1/2022
  • 1 very positive mentions
  • 36 positive mentions
  • 7 negative mentions
  • 16 very negative mentions
Mentions as of
10/31/2022
  • 5 very positive mentions
  • 16 positive mentions
  • 6 negative mentions
  • 4 very negative mentions
Mentions as of
11/30/2022
  • 5 very positive mentions
  • 40 positive mentions
  • 10 negative mentions
  • 25 very negative mentions
Mentions as of
12/30/2022
  • 1 very positive mentions
  • 19 positive mentions
  • 10 negative mentions
  • 10 very negative mentions
Mentions as of
1/29/2023

Current Sentiment

  • 1 very positive mentions
  • 19 positive mentions
  • 10 negative mentions
  • 10 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Cumberland Pharmaceuticals logo
Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, and RediTrex. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.
Read More

Today's Range

Now: $2.73
Low: $2.70
High: $2.78

50 Day Range

MA: $2.37
Low: $2.11
High: $2.75

52 Week Range

Now: $2.73
Low: $1.89
High: $3.81

Volume

3,648 shs

Average Volume

13,329 shs

Market Capitalization

$40.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Cumberland Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Cumberland Pharmaceuticals in the last year: StockNews.com, and TheStreet.
View the latest analyst ratings for CPIX.

What is the current price target for Cumberland Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Cumberland Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Cumberland Pharmaceuticals in the next year.
View the latest price targets for CPIX.

What is the current consensus analyst rating for Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CPIX.

What other companies compete with Cumberland Pharmaceuticals?

Other companies that are similar to Cumberland Pharmaceuticals include Lannett, Assembly Biosciences, Paratek Pharmaceuticals, Omeros and DiaMedica Therapeutics. Learn More about companies similar to Cumberland Pharmaceuticals.

How do I contact Cumberland Pharmaceuticals' investor relations team?

Cumberland Pharmaceuticals' physical mailing address is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. The specialty pharmaceutical company's listed phone number is (615) 255-0068 and its investor relations email address is [email protected] The official website for Cumberland Pharmaceuticals is www.cumberlandpharma.com. Learn More about contacing Cumberland Pharmaceuticals investor relations.